3D Signatures Inc.

3D Signatures Inc. is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of a patient's individual chromosomal arrangement − or signature. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease. Depending on the application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient.

Expert Comments:

Technical analyst Clive Maund takes a look at a biotech stock that he views as a strong buy.
read more >
"3D Signatures Inc. is a company I am excited about. It has a platform technology that looks at a component of a person's DNA and is potentially able to predict the outcome of various medical treatments. It just announced some results from a Hodgkin's lymphoma study. It has also done work on prostate cancer, Alzheimer's, etc. I think it's relatively low risk. On the previous work that it has done, it has shown very strong results and predictive ability. It is currently doing a much larger confirmatory trial in Hodgkin's lymphoma. I like the fact that it's a platform. It has applications for various diseases and medical conditions. The timeline to have a commercial product is much shorter than a traditional biotech company developing a new drug." read more >

Imagine if a simple test of a blood or tissue sample could predict whether the standard treatment of care for a cancer would be effective. That day appears to be near for patients with Hodgkin's lymphoma.
read more >
BioTuesdays (2/20/18)
"3D Signatures Inc. has reported positive results from a preliminary analysis of trial data for Telo-HL, its test for Hodgkin's lymphoma (HL) that is designed to personalize treatment for newly diagnosed patients. . .3DS remains on track to complete all phases of the test development and analytical validation by April 2018. . .3DS focused on HL because the treatment plan for this form of cancer is currently based on a trial and error system of testing different therapies to explore which, if any, a patient responds to. . .TeloView is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer's disease."

One analyst believes 2018 could mark a 'dramatic turnaround' for this biotech company, which is at the forefront of using three-dimensional telomere analysis to personalize medical treatment.
read more >

More Expert Comments

Experts Following This Company

Clive Maund – gold, silver & oil shares
Steve Palmer, President and Chief Investment Officer – AlphaNorth Asset Management

The information provided above is from analysts, newsletters, the company and other contributors.

3D Signatures Inc. is a sponsor of Streetwise Reports.†The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
Disruptive Technology
Software as a Service (SaaS) Business Model
Attracting Industry Majors